Beaird Harris Wealth Management, LLC
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1908938
DALLAS, TX
Position in REGN
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$623
-$149 QoQ
Shares Held
1
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,320
of 1,322 holders
Holding Since
Dec 2022
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Beaird Harris Wealth Management, LLC holds $41,457 across 13 Biotechnology names. REGN ranks #7 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
33 | $16,392 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
41 | $7,678 | |
| 3 | REPL |
Replimune Group, Inc.
|
680 | $7,527 | |
| 4 | MDXG |
Mimedx Group, Inc.
|
1,270 | $4,889 | |
| 5 | ARGX |
Argenx SE
|
2 | $1,855 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
4 | $1,204 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
1 | $623 | |
| 8 | INCY |
Incyte Corp
|
5 | $566 |
All Filings in REGN
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $623 | 1 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $772 | 1 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $771 | 1 | Shares | Sole | 2026-02-23 | |
| 2025-09-30 | $562 | 1 | Shares | Sole | 2025-11-13 | |
| 2025-03-31 | $3,171 | 5 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,561 | 5 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $5,256 | 5 | Shares | Sole | 2024-12-02 | |
| 2024-06-30 | $5,255 | 5 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $4,812 | 5 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $4,391 | 5 | Shares | Sole | 2024-02-27 | |
| 2022-12-31 | $16,594 | 23 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||